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There is a striking similarity between the mechanisms involved in the activation of 
the complement system and those of the Hageman factor-dependent  pathways that 
lead to blood coagulation, fibrinolysis, and kinin formation  Both systems require an 
initial contact with an activator which in turn triggers a cascade of reactions involving 
the sequential interactions of a series of enzymes and regulators. Furthermore, certain 
pro_reins  seem  to operate  as  regulators  of both  systems. The serum  C1  inactivator 
(CI-INA),  1 an  inhibitor  of activated C1  that  is  absent  in  patients  with  hereditary 
angioedema (1), is known to inhibit the activities ofplasmin (2, 3), activated Ha_geman 
factor (2-5), anaphylatoxin inactivator (2), Factor XIa (6), kallikrein (2,  7),C lr,  and 
Cls  (2,  3)  through  the  formation  of stoichiometric  complexes.  In  the  absence  of 
C 1-INA, activated Hageman factor may activate the kinin  system by conversion of 
prekallikrein  to  kallikrein,  which  in  turn  cleaves  bradykinin  from  high  molecular 
weight  kininogen.  Since  bradykinin  is  a  potent  mediator  of  enhanced  vascular 
permeability,  the  pathogenesis  of hereditary  angioedema  may involve interactions 
between  the  Hageman  factor-dependent  pathways  and  the  classical  pathway  of 
complement  activation.  Previous evidence has suggested that  C 1 activation  in  this 
disease is Hageman factor dependent  (8).  Plasmin has been shown to be capable of 
activating C 1 (9) and may represent one such enzyme. 
In the following report, we present evidence that Hageman factor fragment (HFf) 
efficiently activates the complement system via the classical pathway. Native Hage- 
man  factor is a  single-chain fl-globulin  (80,000  mol we)  circulating  in  plasma in  a 
zymogen form at a concentration of ~20-45 #g/ml  (10).  When activated, Hageman 
factor is converted to HFa (Factor XIIa), a serine protease composed of a heavy chain 
and a  light chain held  together by disulfide bonds  (11).  Another  form of activated 
Hageman factor is the 28,000-mol wt fragment designated HFf (12).  HFf is a  weak 
coagulant enzyme because it lacks the binding site for initiating surfaces; on the other 
hand, it is a potent activator of prekallikrein (1~). 
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1 Abbreviations used in this paper." C 1-INA, serum C 1 inactivator; C2D, serum genetically deficient in C2; 
EA, sheep erythrocytes  sensitized with rabbit antibody; GPS-EDTA, guinea pig serum diluted 1:50 with 
0.04 M EDTA-GVB; GVB, veronal-buffered  saline containing 0.1% gelatin; HF, Hageman factor; HFa, 
activated Hageman factor; HFf, Hageman factor fragment; NHS, normal human serum; SDS, sodium 
dodecyl sulfate. 
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Materials  and  Methods 
Buffers.  The  following buffers were  used:  VB,  isotonic veronal-buffered saline,  pH  7.4; 
VB ++, VB containing 0.15  mM CaCI2 and 0.5  mM  MgCI2; GVB +÷, VB ++ containing 0.1% 
gelatin; GVB-E, VB containing 0.1% gelatin and 0.01 M  EDTA; SGVB ++, GVB +÷ containing 
2.5%  (wt/vol) sucrose; Mg-EGTA, 0.1  M  MgC12, 0.1  M  EGTA adjusted to pH 7.0;  and Mg- 
GVB, VB containing 0.5 mM MgCIz and 0.1%  gelatin was prepared according to published 
procedures (13). 
Purified Proteins.  Macromolecular C1  was purified according to a  procedure described by 
Nelson et al. (14),  from serum that was made free of plasminogen by passage over a  Lysine- 
Sepharose 6B immunoadsorbent column (15) equilibrated with veronal-buffered saline, pH 7.0, 
containing 0.15  M  NaCI, 0.02 M  sodium barbital, 0.01  M  MgCia, and 3 mM CaCI2. Highly 
purified Hageman factor (HF), activated Hageman factor (HFa), and Hageman factor frag- 
ment (HFf), were prepared according to the method of Silverberg et al. (16), which consisted 
of the following steps: dialysis of highly purified HF against 10 mM sodium phosphate, pH 8.0, 
containing 0.15 M  NaCI, followed by digestion of HF with 4.0 IU of kallikrein activity/mg of 
HF for  16  h  at  37°C  in  plastic tubes.  The  mixture was applied to a  QAE-Sephadex A-50 
equilibrated with sodium phosphate buffer, pH 8.0.  Kallikrein was recovered in the effluent, 
and  HFa and  HFf were  eluted with  a  NaCI  concentration  gradient,  with  10  mM  sodium 
phosphate buffer, pH 8.0, containing 0.6 M  NaCI as limit buffer. C1 (17), C2 (18), C3 (19), C4 
(20), and C5 (21) were isolated according to published procedures. 
Purification and Aggregation of IgG.  Human  IgG was  isolated from  serum  by a  single-step 
chromatography  on  a  column  of  DEAE  Aft-Gel  Blue,  according  to  the  manufacturer's 
specifications (Bio-Rad Laboratories, Richmond, Calif.). The column (3 ×  25 cm) was packed 
with a  total bed volume of 7 ml/ml of serum to be processed, and equilibrated with starting 
buffer containing 0.02 M  K2HPO4 and 0.02%  NaNa at pH 8.0. After dialysis against the same 
buffer for 10 h at 4°C, the serum was applied to the column and eluted with two bed volumes 
of starting buffer. The IgG-containing fractions (first peak) were pooled and concentrated. 
Aggregation of such purified IgG was performed by incubation at 63°C  for 20  rain at  10 
mg/ml concentration. Particulate aggregates were removed by centrifugation at  200 g  for 5 
rain. The supernate was used as soluble aggregated IgG. 
Antisera.  Monospecific antisera to Clq, Clr, Cls, C2, C3, C4, and Factor B were raised in 
rabbits. 
Immunochemical Analyses.  Radial double or single immunodiffusion analyses were carried out 
in 0.8%  agarose in barbital-buffered saline, pH  7.2,  containing 2.5  mM  CaC12 and 0.09  M 
NaC! at 4°C for 48 h as described (22).  Immunoelectrophoresis was performed in  1% agar or 
0.8% agarose in barbital-buffered saline, pH 8.6, containing 0.09 M NaCI and 2.5 mM calcium, 
at 4.7 V/era at 4°C for 2 h. Sodium dodecyl sulfate (SDS) (9%) polyacrylamide gel electropho- 
resis was performed according to Laemmli (23). 
Sera.  Fresh  human  serum  was obtained  from  healthy donors.  Alternatively, serum  was 
obtained from outdated plasma (purchased from Intercounty Blood Services, Melville, N. Y.) 
by clotting for  12 h  at 4°C upon addition of CaC12 to a  final concentration of 20 raM, and 
centrifugation at  10,000  rpm (Sorvail RC-5B, DuPont  Instruments-Sorvall Biomedical Div., 
Newtown, Conn.). C2-deficient serum (C2D) was a generous gift from Dr. Max Hamburger of 
our laboratory. Guinea pig serum was made into a  1:50 dilution with 0.04 M EDTA-containing 
GVB (GPS-EDTA). 
Preparation of Potassium Thiocyanate (KSCN)- Treated Serum.  For titrations of C3 and C5, C6- 
C9 serum was prepared by incubation of guinea pig serum with an equal volume of cold 1 M 
KSCN for 20 h at 4°C (24, 25). After addition of hydrazine hydrate to a final concentration of 
0.015  M,  the mixture was incubated for 45  min at  37°C,  dialyzed against veronal-buffered 
saline, pH 7.4, with several changes of buffer, and used in experiments. 
Preparation of Complement-containing Cellular Intermediates.  The preparation of sheep erythro- 
cytes sensitized with rabbit antibody (EA), and complement-carrying EA, EAC1, EAC14 (17), 
EAC142  (26),  and  EAC1423  (27)  has been  previously described. Briefly, 5  ml  of EA  (1  × 
109/ml) was incubated with 0.5 ml of C1 for 15 min at 37°C. The cells were washed once with 
warm GVB  ++ (kept at 37°C)  and resuspended to original volume as EAC1. Then  1 mi EAC1 
(1  ×  109/ml) cells were further processed to form EAC4 by incubation with  100/~g of isolated B.  GHEBREHIWET,  M.  SILVERBERG,  AND A. P.  KAPLAN  667 
and fully active 124 for 30 min at 37°C, washed with 0.01  M  EDTA-GVB, followed by two 
washes with GVB  ++ and resuspended in GVB  ++. EACI4 cells for [22 titration were prepared 
by further incubation of EAC4 cells with C1 as described above. EAC142 cells were prepared 
by incubation of EAC14 cells with (]2 for 10 min at 30°C and EAC1423 by incubation with 
C3 as described elsewhere (27). 
Hemolytic Assays.  Various concentrations of HF, HFf, or Hfa were tested for their effect on 
serum complement by incubation with  10 #l of normal human  serum  (NHS)  for 60 min at 
37°12. Then 0.2 ml of sensitized sheep erythrocytes (EA, 5 ×  10S/ml)  were added, the volume 
was  adjusted  to 0.4  ml  with 0.1%  gelatin containing veronal buffer  (GVB++),  and  further 
incubated for 60 min at 37°C. The reaction was stopped by addition of 1.6 ml of cold GVB  ++, 
the mixture was centrifuged, and free hemoglobin was measured in the supernate at 412  nM. 
Determination of 12H~o (28) and individual complement titrations of (21  (13),  C2  (18),  C3 
(26), (24 (17), and (25 (25) were performed according to previously published methods. 
Hemolytic Assay  for the Alternative Pathway.  To determine the effect of HFf on the alternative 
pathway of complement activation, 122D serum or NHS  containing 5  mM  Mg-EGTA was 
incubated  with  either  50  #g/ml  HFf or GVB  for  60  min  at  37°12. Then  5  ×  l07  rabbit 
erythrocytes (ER) were incubated with 25/~l of such treated serum for 60 min at 37°C in a total 
volume of 0.2 ml Mg-GVB. The reaction was stopped with 1 ml cold GVBE and the released 
hemoglobin was determined after centrifugation. 
Kinetics of HFf-dependent Activation of Complement.  NHS (1 ml) was incubated with 50 #g HFf 
for various lengths of time ranging from 0-60  min.  Then  0.1-ml aliquots were removed at 
different time intervals and assayed for residual complement hemolytic activity as described 
above. 
Results 
Depletion  of Complement Hemolytic  Activity  by HFf  In  all  our  experiments,  highly 
purified HF, HFa, or HFf were used. A  representative preparation of HFf and HFa 
is shown in Fig.  1. NHS  (10 #1) was incubated with or without increasing, equimolar 
concentrations  of HF,  HFa,  and  HFf for 60  min  at  37°C.  Then,  0.2  ml  EA  (5  X 
108/ml) was added and further incubated for 30 min at 37°C in a  final volume of 0.4 
ml GVB ÷+. The reaction was stopped with  1.6 ml cold GVB ÷+ and centrifuged, and 
the amount of hemolysis was determined spectrophotometrically at 412 nm. The data 
shown  in  Fig.  2  show  that  HFf was  capable of abrogating complement  hemolytic 
activity in a dose-dependent fashion. The reduction of hemolytic activity was maximal 
upon  addition  of  5  #g  HFf.  On  the  other  hand,  no  activity  was  observed  with 
equimolar concentrations of either the native form of HF, or the two-chain activated 
form of HF (HFa). Depletion of hemolytic activity as a  function of time of incubation 
at  37°C  is shown  in  Fig.  3.  Maximal consumption  of complement  occurred  at  an 
incubation  period  of 60  min  at  a  50  #g/ml  HFf.  Fig.  4  depicts  the  result  of  a 
representative experiment in which NHS human serum  (0.1  ml) was incubated with 
5 #g HFf or 2  mg/ml  aggregated IgG, which  under similar conditions is known  to 
deplete complement hemolytic activity (22). After incubation the mixture was made 
into a  1:100  dilution with GVB ++, and samples ranging from 0.5-1  ml were mixed 
with 0.2 ml EA (5 X  108/ml) in a total volume of 1.5 ml GVB ++ and further incubated 
for 60 min at 37°C.  The tubes were then centrifuged and the degree of hemolysis in 
the supernatant  fluids was determined spectrophotometrically at 412  nm.  The total 
hemolytic complement  activity was  found to be completely abrogated in the serum 
pretreated with HFf or aggregated IgG. 
Effect of HFf on the Alternative Pathway of Complement.  To determine the effect of HFf 
on the alternative pathway, C2D serum, or NHS in 5 mM  Mg-EGTA that had been 
pretreated with 50 #g/ml HFf, or GVB was incubated with 5 X  107 rabbit erythrocytes 668  HAGEMAN  FACTOR-DEPENDENT  COMPLEMENT  ACTIVATION 
FIG.  1.  SDS-polyacrylamide gel electrophoretic analysis of HFf (a and b) and HFa (c and d)  in 
the absence (a and c), and in the presence (b and d), respectively,  of 1% mercaptoethanol. HFf is 
typically a  doublet under nonreducing conditions (a),  but a  single band is seen upon reduction. 
HFa upon reduction gives a characteristic heavy and light chain. 
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FIG.  2.  Depletion of complement  hemolytic  activity  after incubation with  HFf.  NHS  (]0 p.]) was 
incubated with or without equimolar concentrations of HF, HFa, or HFf for 60 min at 37°C. Then, 
0.2 ml EA (5 X  10a/ml)  was added and further incubated for 30 min at 37°C in a final volume of 
0.4 ml GVB  +÷. After incubation, the reaction was stopped with 1.6 ml GVB  ++, centrifuged, and the 
percent hemolysis was calculated from o. d. at 412 nm. 
for  60  min  at  37°C  in  a  total  volume  of 0.2  ml  Mg-GVB.  After  incubation,  the 
reaction was stopped by cold GVB-E  and centrifuged, and  the amount  of hemoglobin 
released was determined  spectrophotometrically.  As summarized  in Table  I, pretreat- 
ment  of C2D  or NHS  containing  Mg-EGTA  with HFfdid  not abrogate  the hemolytic B.  GHEBREHIWET,  M.  SILVERBERG,  AND  A.  P.  KAPLAN  669 
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FIG.  3.  Consumption of complement by HFf as a function of time of incubation. NHS (1 ml) was 
incubated with 50/~g HFf. At various time intervals, 0.1 ml was removed and assayed for residual 
complement hemolytic activity as described in Materials and Methods. Incubation was carried out 
up to 60 min. 
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Fro.  4.  Comparison  of effects of aggregated  Ig43 and  HFf  on serum complement.  0.1  ml of NHS 
was incubated with either HFf (5 ittg) or aggregated IgG  (2 mg/ml)  for 60 min at  37°C.  After 
incubation the mixture was made into a  1  : 100 dilution with GVB  ÷+, and samples ranging from 0.5- 
1 ml were mixed with 0.2 ml EA (5 ×  10a/ml)  in a  total volume of 1.5 ml GVB  ÷+ and further 
incubated for 30 min. The tubes were then centrifuged and the degree of hemolysis was determined 
spect  rophotomet  rically. 
activity,  indicating  that  HFf  under  these conditions does not  initiate the alternative 
pathway  of complement  activation. In addition, Factor B  or C3 in such treated serum 
were  shown  to  be  intact  as  assessed  by  immunoelectrophoretic  analysis  (data  not 
shown). 
Consumption of Individual Complement Components by HFf  To  determine  whether  HFf 
abrogates  the  hemolytic  activity  of  complement  by  sequential  activation  of  the 
classical complement  components  or inactivation of individual components,  titrations 
of  C1,  (32,  (33,  C4,  and  (35  were  performed  on  serum  (0.1  ml)  that  had  been 
preincubated  with 5 #g HFf for 60 min at 37°(3. The  results of representative titration 
experiments  are shown  in Fig.  5  for CI  and  Fig.  6  for (34.  Depletion  of components 670  HAGEMAN  FACTOR-DEPENDENT  COMPLEMENT  ACTIVATION 
TABLE  I 
Effect of HFf on the Alternative Pathway 
Reaction mixture  Lysis  Inhibition 
%  % 
ER +  C2D  68  -- 
Ea +  (C2D +  HFf)  70  0 
ER +  NHS-Mg-EGTA  75  -- 
ER +  (NHS-Mg-EGTA +  HFt)  67  11 
* C2D or NHS containing 5 mM MgoEGTA was preincubated with 50 #g/ml 
HFf or GVB. Then 25 #1 of such treated serum was incubated with 5 x  107 
ER for 60 rain at 37°C. Residual hemolytic  complement was then determined 
as described in Materials and Methods. 
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FIG.  5.  Reduction of the activity of C1  in  human serum  after incubation with  HFf.  Different 
amounts of a  1:100  dilution, HFf-treated or nontreated serum was incubated with 0.1  ml EAC4 (5 
x  10S/ml)  for 10 min at 30°C in a  total volume of 0.5 ml SGVB ++. Then 0.05 ml of C2 (20/~g/ml) 
was added and incubated for  10 rnin at 30°C. The reaction mixture was further incubated for 60 
rain  at  37°C  after  addition of  1:50  dilution of GPS-EDTA  (GVB  containing 0.04  M  EDTA) 
hemolysis in supernate was determined spectrophotometrically at 412 nm after centrifugatlon. 
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FIG. 6.  Reduction of C3  hemolytic activity in serum  after incubation with  HFf.  Experimental 
conditions were as those described in legend to Fig. 5 except that EACI  (5 X  10S/ml) was used. B.  GHEBREHIWET,  M.  SILVERBERG,  AND  A.  P.  KAPLAN  671 
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F[o.  7.  Reduction  of the activity of total  complement and complement components in  human 
serum  after  incubation  with  HFf.  Experimental  conditions  are  as  described  in  Materials  and 
Methods. 
FIo.  8.  Radial double immunodiffusion analysis of macromolecular C 1 in serum incubated with 
either GVB  ++, HFf, or aggregated IgG. Immunodiffusion analysis was carried out in 0.8% agarose 
in barbital-buffered saline, pH  7.2,  containing 2.5 mM CaCI2 and 0.09 M  NaC1 for 48 h  at 4°C 
using specific antibodies to Clq, Clr, and Cls. 
ranged  from 99%  for C1  and  C4  and  91%  for C3  as  shown  in  Fig.  7.  C5  was also 
depleted by 85% (data not shown). 
In other experiments, the effect of HFf and aggregated IgG on C3 and C4 in serum 
was  tested  by  immunoelectrophoresis.  Human  serum  (0.1  ml)  was  incubated  with 
either 5/~g HFf or  10 mg/ml aggregated IgG for 60 min at 37°C.  After incubation, 
the  volume  was  adjusted  to  0.2  ml  with  GVB  and  immunoelectrophoresis  was 
performed in  1% agar in barbital buffer, pH 8.6, for 2 h  at 4°C.  The ability of HFf 
to cleave C3 and C4 was analogous to that of aggregated IgG as judged by the shift 
in mobility and appearance of cleavage products (data not shown). 
Effect of HFf on the C1 Macromolecule.  The direct effect of HFf on macromolecular 
C1  was  studied  by the  double  immunodiffusion  method  using  anti-Clq,  anti-Clr, 
and anti-C ls as described by Ziccardi and Cooper (22).  NHS (0.1  ml) was incubated 
with or without  30 and 60/tl  of HFf (20/tg/ml)  or  1 and  2  mg/ml aggregated IgG 
(10 mg/ml) for 60 min at 37°C. Immunodiffusion analyses of such treated NHS were 
then  carried out  in 0.8%  agarose in barbital-buffered saline, pH  7.2,  containing  2.5 
mM CaCI2 and 0.09 M  NaCI for 48 h  at 4°C. As shown in Fig. 8, an increase in HFf 
concentration  resulted  in  the  dissociation  of C1,  indicating  activation  of the  C1 
macromolecule. Neither HF nor HFa had any effect on C 1 macromolecule. Similar 
experiments  were  performed  using  plasminogen-free  macromolecular  C1  and  the 
results obtained  (data  not  shown)  were comparable to  those  found  using NHS.  In 672  HAGEMAN FACTOR-DEPENDENT COMPLEMENT ACTIVATION 
addition,  using  Clq-depleted  serum  and  purified  Cls,  an  attempt  was  made  to 
elucidate the mechanism of C1 activation. When C lq-depleted serum was incubated 
with  HFf and  analyzed by radial  immunodiffusion techniques  using antiserum  to 
Clq,  Clr,  and  Cls,  no  spur  formation  or  disappearance  of Clr  antigenicity was 
observed, which indicates that C1 was not activated. Furthermore, incubation of C ls 
with  HFf did not result in activation of C ls as assessed by immunoelectrophoretic 
analysis (data not shown). 
Discussion 
The  interaction between  the  complement  system  and  the  cascade  that  leads  to 
blood coagulation and kinin formation has been documented (28-30).  Plasma kalli- 
krein has been shown to inactivate C 1 (31) and plasmin was found to activate it (9). 
The  data  presented  here  demonstrate  that  HFf activates  the  serum  complement 
system in a  manner that is entirely analogous to complement activation by antigen- 
antibody  complexes.  Upon  addition  of HFf to  human  serum,  total  complement 
hemolytic activity was depleted in a dose-dependent fashion (Fig. 2). The activity of 
the individual complement components was also found to be reduced (Fig.  7), with 
maximal depletion occurring at a  dose of 50 #g of HFf/ml of serum added and an 
incubation period of 60 min at 37°C. That the activation of complement proceeded 
via the classical pathway is indicated by the ability of HFf to directly activate and 
dissociate  the  C1  macromolecule  with  concomitant  release  of Clq  and  Cls  and 
disappearance of C lr antigenicity as assessed by single and double radial  immuno- 
diffusion studies  using antisera  to Clq,  Clr,  and  Cls.  Native,  macromo'lecular C1 
gives a continuous line of precipitation with antisera to C 1  q, C l r, and C l s in double 
diffusion as was previously shown by Ziccardi and Cooper (22).  Upon incubation of 
serum with complement activators, however, spurring of the C ls precipitin line over 
that of macromolecular C 1 occurred, indicating release of C ls from activated C 1 (22). 
Furthermore,  the  hemolytic and  immunoelectrophoretic experiments used  demon- 
strated  depletion  of C2,  C4,  and  C3.  In  addition,  when  the  effect of HFf on  the 
alternative  pathway  was  directly  investigated  using  C2D  serum  or  NHS  in  the 
presence of 5  mM  Mg-EGTA and  rabbit  erythrocytes, no reduction  of hemolytic 
activity was observed. This suggests that HFf does not, under these conditions, initiate 
the  alternative  pathway  of complement.  In  the  HF-dependent  pathway  of blood 
coagulation, fibrinolysis, and  kinin  formation, the native molecule HF is bound  to 
appropriate surfaces and activated, resulting in two cleavage products, HFa and HFf, 
both of which possess activity (10). In the present studies, however, neither the native 
molecule nor HFa was capable of depleting complement hemolytic activity. 
Although kallikrein was used in the digestion of native HF to produce HFa and 
HFf, the preparations of HFf used in our studies were free of kallikrein (16) as assessed 
by SDS  gel analysis and  functional analysis using a  variety of synthetic substrates 
(16). Furthermore, the sequential activation of  C4, C2, and C3 suggests that activation, 
not inactivation, of C1 has taken place. It has been reported recently that the major 
effect of kallikrein on C 1 is inactivation (31). The mechanism of this HFf-dependent 
complement activation is not yet clear. However, preliminary experiments using C i q- 
depleted serum have revealed that the intact C 1 macromolecule may be required for 
C 1 activation in serum. When C lq-depleted serum was incubated with HFf or GVB 
and then analyzed by radial double immunodiffusion techniques using monospecific B.  GHEBREHIWET,  M.  SILVERBERG, AND  A.  P.  KAPLAN  673 
antisera to C 1  q, C l r, and C l s, no detectable spur formation or disappearance of C 1  r 
antigenicity was observed. In addition, incubation of highly purified C ls with HFf 
did not significantly shift the mobility of C ls as assessed by immunoelectrophoretic 
analysis (B. Ghebrehiwet, manuscript in preparation). 
The biological implications of the described phenomena could be of great signifi- 
cance in view of the participation of the complement system and the HF-dependent 
pathways  in the production and  release of mediators of vascular permeability. HF 
plays a  pivotal role in the activation of plasma prekallikrein to kallikrein which in 
turn  cleaves  high  molecular  weight  kininogen  to  produce  bradykinin,  a  potent 
mediator of vascular permeability  (1{3). Activation of the complement system also 
leads to the production and release of vasoactive peptides C3a, C4a, and C5a, which 
constitute  the  complement-derived anaphylatoxins  (32).  In  addition,  a  heat-stable 
kininlike  peptide  which  has  the  ability  to  induce  vascular  permeability has  been 
generated in the plasma of hereditary angioedema patients (HAE). In normal serum, 
CI-INA,  an  inhibitor  of activated  CI,  is  also  known  to  inhibit  the  functions  of 
activated  HF  (4,  5).  However,  in  sera  of HAE  patients  which  are  known  to  be 
genetically deficient in C I-INA  (1), uninhibited  activation of C1  may lead  to the 
activation of the complement system elaborating thereby pathogenic peptide(s) which 
enhance vascular permeability. It has recently been reported by this laboratory (16) 
that HF autoactivated upon binding to surfaces if as little as one active molecule in 
5,000  is  present.  The  possibility  of such  autoactivation  of HF  in  vivo cannot  be 
determined at this point. However, it is possible that tissue injury initiates autoacti- 
vation of HF to release HFf, which in turn can activate the complement system. This 
kind of activation may thus represent one mechanism by which vasoactive peptides 
that  play  a  role  in  HAE  and  other  inflammatory  reactions  could  be  released. 
Furthermore, in patients with  gouty inflammation, monosodium urate crystals are 
believed to initiate the pathogenesis of the disease (33,  35). In addition to activation 
of the classical pathway of complement, (35, 36), urate crystals have been shown to 
activate HF in human plasma and synovial fluid (37). That complement participates 
in the pathogenesis of gout has been reported previously (33,  34).  In view of these 
findings, it is possible to postulate that activated HF may participate in the patho- 
genesis  of this  disease  by  either  converting  high  molecular  weight  kininogen  to 
produce  bradykinin  or  activating  the  complement  system  to  produce  vasoactive 
peptides.  Using highly purified Clq, Clr, and Cls, further studies are underway to 
elucidate the mechanisms by which HFf activates the complement system. More work 
is also necessary to elaborate on the biological implication of the described phenom- 
enon. 
Summary 
A fragment of activated Hageman factor (HFf) has been demonstrated to activate 
the classical pathway of complement in a  manner that is analogous to complement 
activation by antigen-antibody complexes or aggregated IgG. Thus C 1, C4, C2, C3, 
and C5  were found to be depleted on addition of HFf to serum. The reduction of 
serum hemolytic activity was maximal upon addition of 5 #g HFf and an incubation 
time of 60 min at  37°C.  Consumption of the total complement activity and of the 
individual components proceeded in a dose-dependent fashion. No comparable activ- 
ity was observed when equimolar concentrations of either the native Hageman factor 674  HAGEMAN FACTOR-DEPENDENT COMPLEMENT  ACTIVATION 
(HF) or the two-chain activated form of Hageman factor (HFa) were incubated with 
serum. Further, the ability of HFf to convert serum C3 and C4 was similar to that of 
aggregated IgG as assessed by immunoelectrophoresis. This function of HFf appeared 
to  be  independent  of plasminogen  (or  plasmin)  since  plasminogen-free serum  was 
indistinguishable from  normal serum.  Radial double immunodiffusion  experiments 
using  antiserum  to  Clq,  Clr,  and  Cls  on  HFf-treated  serum  demonstrated  the 
dissociation  of the  C1  trimolecular  complex,  with  concomitant  reduction  of Clr 
antigenicity  that  is  indicative of C1  activation.  Thus,  HFf appears  to  lead  to  C1 
activation upon incubation with serum or when incubated with partially purified C 1. 
This may represent a control link between activation of the intrinsic coagulation-kinin 
pathway and the initiation of the classical complement cascade. 
The  authors  thank  Bruce  Randazzo and  Lily Soirez for skillful technical assistance and 
Karen Randall for excellent secretarial work. 
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